Bone Marrow Transplant Clinical Trial
Official title:
An Online Wellness Intervention for Bone Marrow Transplant Survivors
Verified date | March 2020 |
Source | Arizona State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Specific aim #1: Assess feasibility (i.e., acceptability, practicality, demand, limited efficacy) of a home-based, online yoga intervention in patients following allogeneic stem cell transplant. Feasibility benchmarks will include: >70% satisfied with the intervention and >70% intending to continue participating in online yoga (i.e., acceptability); >70% of participants achieving an average of >42 min/week (70% of presceibed 60 min/week) of online yoga throughout the 12-week intervention (i.e., demand); >70% completing questionnaires across all four time points (i.e., practicality); at least small effect sizes of the intervention on physical function, fatigue, anxiety, sleep disturbance, social functioning, pain interference, depression, and quality of life as compared to a podcast control group (i.e., limited efficacy).
Status | Completed |
Enrollment | 41 |
Est. completion date | March 25, 2020 |
Est. primary completion date | March 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 1) have received a bone marrow transplant 6 months ago - 2) have a cancer diagnosis - 3) no active infections - 4) platelet count >50 - 5) answer "no" to all items on the Physical Activity Readiness Questionnaire (PAR-Q), or be willing to obtain a signed medical release from their physician in the case that a question is answered with a "yes" - 6) have access to a desktop or laptop on a regular basis - 7) have access to reliable internet - 8) read and understand English - 9) age 18 years or older - 10) willing to be randomized to one of two groups Exclusion Criteria: - 1) Engagement in yoga in the past year - 2) currently engage in =150 min/week of moderate-/vigorous-intensity physical activity on a weekly basis - 3) have a history of syncope in last 2 months - 4) have a history of recurrent falls (=2 in 2 months) - 5) Any planned change in pharmacologic intervention (i.e., new drug) during the study interval (i.e., 20 weeks) - 6) have an Eastern Cooperative Oncology Group 3 (ECOG 3) questionnaire score greater than three - 7) currently utilize Udaya.com - 8) currently pregnant - 9) currently reside outside of the United States of America |
Country | Name | City | State |
---|---|---|---|
United States | Arizona State University | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
Arizona State University | Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical Function | This measure is captured through the PROMIS-29 Physical Function Subscale. Raw scores can range from 4-20, with higher scores indicating better physical function. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Anxiety | This measure is captured through the PROMIS-29 Anxiety Subscale. Raw scores range from 4-20, with higher scores indicating more anxiety. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Depression | This measure is captured through the PROMIS-29 Depression Subscale. Raw scores range from 4-20, with higher scores indicating more depression. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Fatigue | This measure is captured through the PROMIS-29 Fatigue Subscale. Raw scores range from 4-20, with higher scores indicating more fatigue. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Sleep Disturbance | This measure is captured through the PROMIS-29 Sleep Disturbance Subscale. Raw scores range from 4-20, with higher scores indicating more sleep disturbance. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Ability to Participate in Social Roles and Activities | This measure is captured through the PROMIS-29 Ability to Participate in Social Roles and Activities Subscale. Raw scores range from 4-20, with higher scores indicating a better ability to participate in social roles and activities. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Pain Interference | This measure is captured through the PROMIS-29 Pain Interference Subscale. Raw scores range from 4-20, with higher scores indicating more interference of pain in daily life. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Pain Intensity | This measure is captured through the PROMIS-29 Pain Intensity Subscale. This is a single-item question asking the participant to rate their average level of pain on a 0-10 scale, with a higher score indicating worse pain. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Physical Health | This measure is captured through the PROMIS Global Health Physical Subscale. Raw scores range from 2-10, with higher scores indicating better physical health. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Chronic Graft vs. Host Disease Symptoms | This measure is captured with the Lee Symptom Score, which assesses various symptoms commonly associated with Graft vs. Host Disease. Raw scores range from 0-120, with higher scores indicating higher symptom burden. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Primary | Mental Health | This measure is captured through the PROMIS Global Health Mental Health Subscale. Raw scores range from 2-10, with higher scores indicating better mental health. | Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20) | |
Secondary | Objective Physical Activity | Objective physical activity will be collected with the Fitbit Flex 2 device. This device captures light, moderate, and vigorous-intensity activity via an accelerometer. | Daily physical activity throughout the 12-week intervention (baseline through week 12) | |
Secondary | Subjective Physical Activity | Subjective physical activity will be assessed with the Modifiable Activity Questionnaire. This questionnaire asks participants to indicate the days and the durations in which they participated in 39 different activities. Weekly minutes of activity is calculated from the information provided. | Weekly physical activity throughout the 12-week intervention (baseline through week 12) | |
Secondary | Objective Yoga/Podcast Participation | Participation in yoga or podcasts is collected through the number of minutes spent viewing/watching/listening to the yoga videos and podcast sessions. | Weekly throughout the 12-week intervention (baseline through week 12) | |
Secondary | Subjective Yoga/Podcast Participation | Participation in yoga or podcasts is collected through self-report yoga or podcast logs. | Weekly throughout the 12-week intervention (baseline through week 12) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02451462 -
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
|
N/A | |
Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
Active, not recruiting |
NCT04395222 -
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT05603156 -
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
|
N/A | |
Completed |
NCT03530969 -
Geriatric Communication Skills Training Program for Oncology Clinicians
|
N/A | |
Recruiting |
NCT04115241 -
Activity Levels in Bone Marrow Transplant Patients
|
||
Completed |
NCT00143780 -
Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination
|
Phase 4 | |
Completed |
NCT05662631 -
Remote Monitoring and Home-based Health Care for Treatment of Bone Marrow Transplant Patients
|
N/A | |
Completed |
NCT03028961 -
Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02575079 -
Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT
|
N/A | |
Active, not recruiting |
NCT02665065 -
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
Completed |
NCT01735565 -
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT04041219 -
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
|
Phase 4 | |
Not yet recruiting |
NCT06361173 -
Spanish BMT4me Usability & Acceptability
|
||
Completed |
NCT03030248 -
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
|
Phase 2 | |
Completed |
NCT00695123 -
Screening for Subjects to Participate in Studies of Blood Disorders
|
||
Terminated |
NCT02057289 -
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
|
Phase 1 | |
Completed |
NCT04275830 -
The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients
|
N/A | |
Completed |
NCT03245788 -
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
|
N/A | |
Completed |
NCT03758911 -
Perspectives on Bone Marrow Donors Who Donate for Their Parent
|